Nebenwirkungen · Onerji
Onerji (60 mg + 7.5 mg)/mL solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-152967 · Präparat HOS-100875
Neuropathy In clinical studies, 3% of the Parkinson’s disease patients treated with Onerji developed peripheral neuropathy (see section 4.4). All cases were classified as subacute or chronic, and 84% of events were of mild or moderate severity. Neuropathy was most often characterised as sensory or sensorimotor. Most cases were reported in association with low vitamin B levels (78% of cases; 61%, 39% and 17% with low vitamin B6, B9 or B12 levels, respectively) and high levodopa daily dose. Treatment was discontinued in 0.7% of patients due to neuropathy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-23T10:32:00Z · SHA-256 0a3b093da64a9acdd1634c12578cb8b735dccbd1f74b12bfa050312b0763b0d8 · Passage 5ef034f970e38e48d9e4aee2499dd50702a699843866f6676fa3101159899f4e · Zeichen 11958–12517 im Abschnitt